Sutro Bio joins biotech’s zombie army

The company is determined to persist with its plans in the face of signs it shouldn't, Adam Feuerstein writes.

March 21, 2025 Check out STAT+

Sponsored By

Molly Ferguson/STAT STAT+ | Sutro Bio joins biotech's zombie army. When will this insanity end? In this edition of "Adam's Biotech Scorecard," a closer look at a company that appears determined to persist in its plans in the face of signs it shouldn't. By Adam Feuerstein STAT+ | After a big donor sought care from a Dana-Farber cancer doctor, things went awry A doctor's failure to keep medical records violated state regulations and ethical standards for physicians, a legal complaint contends. By Liz Kowalczyk — Boston Globe STAT+ | Mass General Brigham to invest $400 million to open new cancer institute before Dana-Farber partnership ends The project will be completed before fall of 2028, when Dana-Farber ends its longtime adult oncology partnership with Mass General Brigham. By Jonathan Saltzman — Boston Globe SEBASTIEN BOZON/AFP via Getty Images STAT+ | Belgian anti-trust authorities probe Roche for allegedly delaying biosimilars of two cancer meds The probe is the latest effort by the European Commission and European countries to scrutinize potential antitrust behavior by drugmakers By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser